SCHEMBL10116547

SCHEMBL10116547

Cc1cc(N2CC(C)O[C@H](C)C2)c(C)cc1NC(=O)c1ccc(NS(=O)(=O)C(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.43
KDM4E B2RXH2 4/20 0.41
LMNA P02545 3/20 0.41
CRHBP P24387 2/20 0.41
CRHR2 Q13324 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MAPT P10636 2/20 0.41
GSK3B P49841 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13204918 1.00 THRB (0.43) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10133544 1.00 THRB (0.43) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10116479 0.89 THRB (0.46) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10134225 0.88 THRB (0.40) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10116598 0.88 THRB (0.40) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10116262 0.86 CRHBP (0.43) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10116239 0.86 KDM4E (0.43) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10133268 0.86 KDM4E (0.43) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10133515 0.86 CRHBP (0.43) THRBKDM4ELMNACRHBPCRHR2
SCHEMBL10116489 0.86 THRB (0.43) THRBLMNACRHBPCRHR2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R THRB 417/4885KDM4E 1627/4885LMNA 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.